We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Letter from Health Minister Jo Churchill confirming Public Health England’s (PHE) priorities for 2021.
Those used in the UK as effective at preventing symptomatic disease in the majority of people with underlying health conditions as the rest of the population.
Public Health England (PHE) has today announced the first group of countries who will receive genomic sequencing support through the New Variant Assessment Platform (NVAP).
The Joint Committee on Vaccination and Immunisation (JCVI) has been asked to consider the options for a potential coronavirus (COVID-19) booster programme.
New analysis suggests the vaccination programme has prevented between 6.4 and 7.9 million infections and 26,000 and 28,000 deaths in England alone.
The National Chlamydia Screening Programme (NCSP) will focus testing on women, who are at highest risk of serious consequences from the infection.
New data suggests a low risk of COVID-19 reinfection in the population.
New analysis by PHE shows for the first time that 2 doses of COVID-19 vaccines are highly effective against hospitalisation from the Delta (B.1.617.2) variant.
Service, led by PHE London, was set up in partnership with the Greater London Authority, Guy's and St Thomas' NHS Foundation Trust, borough councils and the City of London Corporation.
New study by PHE shows for the first time that 2 doses of the COVID-19 vaccines are highly effective against the B.1.617.2 variant first identified in India.
The new national public health procurement scheme has gone live to help grow capacity, push innovation and build resilience within microbiology supply chain.
The Joint Committee on Vaccination and Immunisation (JCVI) has issued advice to the government on the use of COVID-19 vaccines to mitigate the impact of the B1.617.2 variant of concern.
New evidence continues to show vaccination is highly effective in protecting against death and hospitalisation from coronavirus (COVID-19).
The Joint Committee on Vaccination and Immunisation (JCVI) has issued advice to the UK government on the use of the coronavirus (COVID-19) Oxford/AstraZeneca vaccine for people aged under 40.
Round 4 of the Schools Infection Survey (SIS) shows a significant drop in the number of secondary school pupils and staff testing positive for coronavirus (COVID-19).
New study to offer daily rapid testing to contacts of positive COVID-19 cases.
This letter sets out the changes to the Pneumococcal Polysaccharide Vaccine (PPV) supply route from 1 June 2021.
A new study by Public Health England (PHE) has shown that one dose of the COVID-19 vaccine reduces household transmission by up to half.
The JCVI has advised that pregnant women should be offered the COVID-19 vaccine at the same time as the rest of the population, based on their age and clinical risk group.
PHE analysis suggests the UK COVID-19 vaccination programme has so far prevented thousands of deaths in those aged 60 and above.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.